(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.36%) $82.71
(6.71%) $2.05
(0.00%) $2 347.30
(-0.35%) $27.44
(4.08%) $959.75
(-0.22%) $0.933
(-0.35%) $10.99
(-0.53%) $0.796
(1.55%) $93.30
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.31%
1.05% $ 892.48
@ $890.19
Ausgestellt: 29 Apr 2024 @ 20:36
Rendite: 0.26%
Vorheriges Signal: Apr 29 - 15:30
Vorheriges Signal:
Rendite: 0.31 %
Live Chart Being Loaded With Signals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion...
Stats | |
---|---|
Tagesvolumen | 365 665 |
Durchschnittsvolumen | 466 048 |
Marktkapitalisierung | 96.34B |
EPS | $0 ( 2024-02-02 ) |
Nächstes Ertragsdatum | ( $10.14 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 25.65 |
ATR14 | $14.58 (1.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Ryan Arthur F | Sell | 2 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 2 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 9 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 15 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 14 | Common Stock |
INSIDER POWER |
---|
-29.89 |
Last 100 transactions |
Buy: 231 452 | Sell: 428 529 |
Volumen Korrelation
Regeneron Pharmaceuticals Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Regeneron Pharmaceuticals Korrelation - Währung/Rohstoff
Regeneron Pharmaceuticals Finanzdaten
Annual | 2023 |
Umsatz: | $13.12B |
Bruttogewinn: | $11.30B (86.16 %) |
EPS: | $37.05 |
FY | 2023 |
Umsatz: | $13.12B |
Bruttogewinn: | $11.30B (86.16 %) |
EPS: | $37.05 |
FY | 2022 |
Umsatz: | $12.17B |
Bruttogewinn: | $10.61B (87.18 %) |
EPS: | $40.51 |
FY | 2021 |
Umsatz: | $16.07B |
Bruttogewinn: | $13.63B (84.83 %) |
EPS: | $76.40 |
Financial Reports:
Symbol | Period | Year | Title |
---|---|---|---|
REGN | Q4 | 2023 | Financial Report for REGN - Q4 2023 |
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.